Amidst the ongoing Covid-19 pandemic ISSAR Pharma announces out-licensing of its peptide-based NCEs

ISSAR Pharma, the only company in India which focuses on research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, opening opportunities for fruitful partnerships 

Hyderabad, May 28, 2021: The Covid-19 pandemic may have brought many economies and businesses to their knees, but India’s pharmaceutical industry stood firm during this critical time. Business stakeholders say the government’s emphasis on promoting the growth of the domestic pharma sector during the pandemic could not have come at a better time.

The explosion of the second wave of Covid-19 cases in India and other developing nations is adding momentum to a push to licensing of the vaccines, putting pressure on pharmaceutical companies to do more to address the crisis. Pharmaceutical companies, which are quickly scaling up production to meet global demand, have announced licensing of many of their entities.

To boost the production of medicines at these tough times of crisis and to fill the gap in the Indian pharma industry, ISSAR Pharmaceuticals (https://issar.co.in/), the pioneer in peptide technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent. The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population, and making it affordable and accessible for better health outcomes.

“We take pride in being India’s first ever company to conduct phase-1 clinical trials, and launch the first ever indigenous peptide drug, Melgain in market for the treatment of Vitiligo in 2004”, informs  Mr. Ramakrishna Reddy Isanaka, Founder and Chairman of  ISSAR Pharmaceuticals.

He also expressed his concerns on how the second wave of the coronavirus pandemic has hit the country and it’s extremely important that more and more people get vaccinated. Terming it a collective crisis, he appealed to the entire pharma community to come together to confront and defeat the ongoing COVID-19 pandemic in the country.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses Solid-phase peptide synthesis as the technology of choice, and has the capability to synthesize custom peptides, API peptides and cosmetic peptides at all scales within a short duration.

With emphasis on quality, safety and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology and diseases of bones and joints.

ISSAR’s FDA – compliant state-of-the-art manufacturing facility of 62000 sq. ft., is purely into peptide manufacturing technology, located in Genome valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing highest standards of purity of up to 99.5% by continued process optimization.

With over 25 years of experience and prime focus in Research and Development, ISSAR’s dedicated team of experts are proud to have developed India’s first ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’s commitment has also led to the development of their second New Chemical Entity called Xylentra, which is the first ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis and Sepsis. Recently, an NCE for the treatment of burn-wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, USA in 2020.